gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HROWHealthcarePharmaceuticals

Harrow, Inc. Common Stock (HROW)

$26.04−9.43%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$26.04▼ 26.48% in range
Nov 5, 2025Low $26.04 · High $54.80Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Harrow closed at $26.04 on Nov 5, down 9.43%, within 0.0% of its 52-week closing low. Volume of 702.1K shares was 1.14× its 20-day average (close to normal).

Split-adjusted performance: -15.0% over one month, -33.3% over six months, -26.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $70.66M, up 10.9% from a year earlier, with a net margin of -24.4%.

Short interest was 7.5M shares at the Oct 15 settlement, down 3.7% from the prior report (24.3% of float, 11.2 days to cover).

Market cap$976.2M37.5M shares
Revenue · quarter$70.7M+10.9% YoY
Diluted EPS$-0.46−453.8% YoY
P/E · TTM—P/S 3.5×
Net margin-24.4%Gross 71.3%
Dividend yieldNone
52-week range26.04 – 54.80−52.5% from high
Volume702.1K1.14× 20-day avg
Volatility · 60d44.2%Annualised
Short % of float24.3%11.2 days to cover
Net cash-$208.5MCash $83.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −13.2%1M −15.0%3M −35.6%6M −33.3%YTD −46.9%1Y −26.3%3Y +81.7%5Y +169.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum45
Revenue growth59
Net margin54
Value (low P/E)—
Size71

Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.

Short interest

Details →
Shares short7.5M−3.7% vs prior
Days to cover11.2Settled Oct 15
% of float24.3%
Short vol. 10d64.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HROWHarrow$26.04−9.43%−33.3%+10.9%−24.4%—$976.2M
JANXJanux Therapeutics$16.06−11.66%+10.5%—−214.0%—$981.9MCompare
MLTXMoonLake Immunotherapeutics$10.80−6.57%−37.2%———$919.2MCompare
MRVIMaravai LifeSciences Holdings$6.98−9.59%+77.2%+8.5%−24.1%—$1.04BCompare
SVRASavara$4.38−6.01%−15.1%———$899.9MCompare
JBIOJade Biosciences$14.10−6.25%−41.8%———$896.7MCompare
ORICOric Pharmaceuticals$8.49−9.10%−3.6%———$880.0MCompare
SPTXSeaport Therapeutics$20.39−2.72%————$1.09BCompare
LTGOLatigo Biotherapeutics$13.01−7.34%————$862.6MCompare

News about Harrow

All news →
Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research · 3d ago▲ PositiveDo Options Traders Know Something About Harrow Stock We Don't?Zacks Investment Research · Oct 9, 2026▼ NegativeHarrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual MeetingGlobeNewswire Inc. · Jul 20, 2026▲ PositiveHarrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric EyecareGlobeNewswire Inc. · Jun 10, 2026▲ PositiveHarrow to Present at William Blair’s 46th Annual Growth Stock ConferenceGlobeNewswire Inc. · May 27, 2026▲ Positive

Quick answers

What does Harrow do?
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market.
What is HROW's market cap?
$976.18M, based on the Nov 5 close of $26.04.
Does Harrow pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HROW is sold short?
7.5M shares, 24.3% of float, as of Oct 15, 2026.
What sector is HROW in?
Healthcare, in the Pharmaceuticals industry.

About Harrow

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

HQ: Nashville, TN373 employeesListed Apr 30, 2007harrow.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology